PR Newswire·Aug 28, 2026, 7:30 AM ET

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

Kazia Therapeutics Limited priced a tranched registered public offering of 2,580,000 ADSs, pre-funded warrants, Series A Warrants, & Series B Warrants.
Series A Warrants allow purchase of up to 2,243,478 ADSs at $17.825 per share, expiring 30 days after the expected second-half 2027 Stage IV TNBC data readout or five years from issuance.
Series B Warrants allow purchase of up to 2,064,000 ADSs at $19.375 per share, expiring 30 days after the expected first-half 2028 HR+/HER2- data readout or five years from issuance.
The combined public offering price is $15.50 per ADS with accompanying warrants, & $15.4999 per pre-funded warrant with accompanying warrants.
Expected gross proceeds from the initial offering are approximately $40 million, with potential additional gross proceeds of approximately $80 million if all warrants are exercised.
The offering is expected to close on or about August 31, 2026.
Net proceeds will primarily fund clinical development of paxalisib for triple-negative breast cancer, HR+/HER2- breast cancer, & other oncology indications, plus working capital.
Leerink Partners & Guggenheim Securities are joint bookrunning managers, while BTIG & Needham & Company are lead managers.
Kazia Therapeutics is an oncology-focused biotechnology company based in Sydney, Australia, developing paxalisib as an investigational PI3K/Akt/mTOR pathway inhibitor.